Virus Or Component Thereof Patents (Class 424/204.1)
  • Patent number: 11560418
    Abstract: The present invention provides Factor IX fusion proteins with higher specific activity and a longer useful clotting function relative to wild type or non-modified Factor IX protein.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: January 24, 2023
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Tal Kafri
  • Patent number: 11484590
    Abstract: The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: November 1, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
  • Patent number: 11402380
    Abstract: This disclosure relates to assays for detecting activating antibodies in a sample that are capable of antibody-dependent cell-mediated cytotoxicity. In certain embodiments, this disclosure relates to target cells comprising an antigen on the exterior of the cells and a luciferase inside the cells. In certain embodiments, the antigen is an Ebola-virus glycoprotein. In certain embodiments, this disclosure relates to detecting changes in chemiluminescence of the luciferase as an indication of activating antibodies in a sample capable of cell lysis when mixed with effector cells.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 2, 2022
    Assignee: Emory University
    Inventors: Paul Spearman, Karnail Singh, Xuemin Chen
  • Patent number: 11331382
    Abstract: Described herein are improved purification methods for Zika virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering said Zika vaccines to subjects in need thereof.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: May 17, 2022
    Assignee: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • Patent number: 11311612
    Abstract: The compositions and methods are described for generating an immune response to a Plasmodium antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to malaria by expressing the Plasmodium antigen in the subject to which the MVA vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat malaria.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: April 26, 2022
    Assignee: Geovax, Inc.
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael Paul McCurley
  • Patent number: 11306284
    Abstract: Methods for introducing exogenous material into a cell are provided, which include exposing the cell to a transient decrease in pressure in the presence of the exogenous material. Also provided are devices for performing the method of the invention.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: April 19, 2022
    Inventor: Ryan Pawell
  • Patent number: 11291836
    Abstract: The disclosure is directed to a device for electroporating and delivering one or more antigens and a method of electroporating and delivering one or more antigens to cells of epidermal tissues using the device. The device comprises a housing, a plurality of electrode arrays projecting from the housing, each electrode array including at least one electrode, a pulse generator electrically coupled to the electrodes, a programmable microcontroller electrically coupled to the pulse generator, and an electrical power source coupled to the pulse generator and the microcontroller. The electrode arrays define spatially separate sites.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: April 5, 2022
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Kate Broderick, Jay McCoy, Stephen V. Kemmerrer
  • Patent number: 11286464
    Abstract: Provided herein is a method for producing an inactivated virus including a) heating the virus to a temperature sufficient to disrupt the virus membrane; b) exposing the virus of step (a) to an RNA degrading enzyme; and c) cooling the virus to a temperature sufficient to reestablish the integrity of the virus membrane. Also provided herein is a vaccine produced using the instant method.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: March 29, 2022
    Assignee: NDSU RESEARCH FOUNDATION
    Inventor: Sheela Ramamoorthy
  • Patent number: 11266732
    Abstract: The present disclosure relates to recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens, which may be used, for example, for the treatment or prevention of infectious disease or cancer. The recombinant RhCMV or HCMV vectors elicit and maintain high level cellular immune responses specific for the heterologous antigen while including deletions in one or more genes essential or augmenting for CMV replication, dissemination or spread.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 8, 2022
    Assignee: Oregon Health & Science University
    Inventors: Louis Picker, Jay A. Nelson, Klaus Frueh, Michael A. Jarvis, Scott G. Hansen
  • Patent number: 11260123
    Abstract: The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable exctpients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: March 1, 2022
    Assignees: SANOFI PASTEUR LIMITED, SANOFI PASTEUR BIOLOGICS, LLC
    Inventors: Stephen Anderson, Simon Delagrave, John Hamberger, Qinglian Li, Sophia Mundle, Nausheen Rahman
  • Patent number: 11185580
    Abstract: Embodiments of the present invention provide compositions and methods for recombinantly generating tagless constructs of proteins or peptides. In certain embodiments, recombinant proteins or peptides disclosed herein concern human papilloma virus (HPV). Other embodiments concern using these constructs in compositions to elicit immune responses in a subject to one or more HPV types. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infections are also disclosed. Nucleic acids and expression vectors coding for constructs contemplated herein are provided. In certain embodiments, an HPV capsid protein generated is devoid of any fusion tags. In addition, truncated forms of HPV L1 are contemplated.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: November 30, 2021
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Robert L. Garcea, Dennis G. Macejak
  • Patent number: 11167033
    Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an inactivated virus in combination with a non-ionic surfactant vesicle (NISV). In certain embodiments at least a portion of the antigen present in the composition is physically associated with the NISV. In certain embodiments the compositions are lyophilized and subsequently rehydrated after a period of storage. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV. In certain embodiments the lyophilized compositions are stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments, the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV and that were also stored at temperatures in excess of 8° C. prior to rehydration.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: November 9, 2021
    Assignee: Variation Biotechnologies Inc.
    Inventor: David E. Anderson
  • Patent number: 11166915
    Abstract: The present invention relates to a method for preparing viral vector-based compositions wherein the viral vector-based particles present in the composition have a particle size distribution with a polydispersity index (PDI) of less than 0.5, the method comprising the steps: (a) providing replication-deficient viral vectors; (b) providing a solution comprising at least one sugar and at least three different excipients selected from hydrophilic and amphiphilic excipients, wherein the excipients are characterized by polar, aliphatic, aromatic, negatively charged, and/or positively charged functional groups, and wherein the solution is further characterized by an excipient-sugar ratio of at least 1:2 (w/w); and (c) mixing the replication deficient viral vectors of step (a) with the solution of step (b).
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: November 9, 2021
    Assignee: Leukocare AG
    Inventors: Kristina Kemter, Martin Scholz
  • Patent number: 11168113
    Abstract: (Technical problems to be solved) Providing a method for selecting an mineral of molybdenum. (Means for solving the problems) A peptide comprising an amino acids sequence according the following formula (1) and/or (2): (1) (ALRKNMD-FCPQSETGWHYIV)-(LIVFA)-(HPWRK)-(TSNQ)-(TSNQ)-(LIVFA)-(TSNQ)-(TSNQ)-(LIVFA)-(FYW)-(LIVFA)-(HPWRK) (2) (LIVFA)-(RHK)-(TSNQ)-(LIVFA)-(LIVFA)-(TSNQ)-(LIVFA)-(LIVFA)-(LIVFA)-(RHK)-(RHK)-(HPW) wherein one amino acid is respectively selected from each group defined by paired parentheses.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: November 9, 2021
    Assignees: SHIBAURA INSTITUTE OF TECHNOLOGY, JX NIPPON MINING & METALS CORPORATION
    Inventors: Mitsuo Yamashita, Akira Miura
  • Patent number: 11141475
    Abstract: Provided are surprisingly effective methods for inactivating pathogens, and for producing highly immunogenic vaccine compositions containing an inactivated pathogen rendered noninfectious by exposure to a Fenton reagent, or by exposure to a Fenton reagent or a component thereof in combination with a methisazone reagent selected from the group consisting of methisazone, methisazone analogs, functional group(s)/substructure(s) of methisazone, and combinations thereof. The methods efficiently inactivate pathogens, while substantially retaining pathogen antigenicity and/or immunogenicity, and are suitable for inactivating pathogens, or for the preparation of vaccines for a wide variety of pathogens with genomes comprising RNA or DNA, including viruses and bacteria. Also provided are highly immunogenic inactivated vaccine compositions prepared by using any of the disclosed methods, and methods for eliciting an immune response in a subject by administering such vaccine compositions.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: October 12, 2021
    Assignee: Najit Technologies, Inc.
    Inventors: Ian J. Amanna, Elizabeth A. Poore
  • Patent number: 11141407
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating AIDS, comprising a rhodanine derivative and a nucleoside reverse transcriptase inhibitor. A complex composition of the present invention exhibits a synergistic effect in terms of anti-HIV activity as compared with a case where each of the compounds is used as a single drug. Thus, the composition provides sufficient anti-HIV activity and exhibits an excellent effect of decreasing side effects such as toxicity even in a case where each compound is administered in a small amount. Accordingly, the present invention is expected to greatly contribute to treatment of AIDS patients.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: October 12, 2021
    Assignee: AVIXGEN INC.
    Inventors: Min Jung Kim, Jun Sub Choi, Hye Cheong Koo, Yi Yong Baek
  • Patent number: 11135280
    Abstract: Provided herein are methods of incorporating substitutions of specified residues into a filovirus GP in order to increase immunogenicity and/or broaden the cross-reactivity of the protective immune response against other filovirus members. Also provided herein are mutant filovirus GPs comprising such substitutions.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: October 5, 2021
    Assignees: INTEGRATED BIOTHERAPEUTICS, INC., INTEGRAL MOLECULAR, INC.
    Inventors: Mohammad Javad Aman, Katie A. Howell, Edgar Davidson, Benjamin J. Doranz
  • Patent number: 11135281
    Abstract: A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: October 5, 2021
    Assignees: Hawaii Biotech, Inc., Infectious Disease Research Institute
    Inventors: David E. Clements, Neal Van Hoeven
  • Patent number: 11065324
    Abstract: The present invention relates to a combination vaccine for swine, comprising non-replicating antigen from porcine circovirus type 2 (PCV2), and live porcine reproductive and respiratory syndrome virus (PRRSV); the combination vaccine is formulated as an oil-in-water emulsion, and is adjuvated with squalane and vitamin E-acetate. This combination vaccine was found to be immunologically effective against all pathogens: PCV2, and PRRSV.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: July 20, 2021
    Assignee: Intervet, Inc.
    Inventors: Theodorus Jansen, Maarten Hendrik Witvliet
  • Patent number: 10968464
    Abstract: Disclosed herein a unique cell line system to generate a novel bovine adenovirus vector that provides more gene insertion capabilities and better immunogenicity for inserted antigens. The unique cell line is used for generating and growing of the new adenovirus vectors for gene delivery or recombinant vaccine production.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: April 6, 2021
    Assignee: Purdue Research Foundation
    Inventor: Suresh Kumar Mittal
  • Patent number: 10954516
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 23, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Patent number: 10946088
    Abstract: A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: March 16, 2021
    Assignee: Seqirus UK Limited
    Inventors: Christoph Haussmann, Frank Hauschild, Bjorn Jobst
  • Patent number: 10940194
    Abstract: Provided are a mutated HPV58 L1 protein or a variant thereof, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein or a variant thereof and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types, and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: March 9, 2021
    Assignees: Xiamen University, Xiamen Innovax Biotech Co., Ltd.
    Inventors: Shaowei Li, Zhihai Li, Shuo Song, Maozhou He, Ying Gu, Ningshao Xia
  • Patent number: 10918845
    Abstract: A transdermal administration device including a first administration member including a first substrate and a first projection protruding from a first administration surface of the first substrate, and a second administration member including a second substrate and a second projection protruding from a second administration surface of the second substrate. The first substrate has an aperture, and the second substrate is positioned within the aperture when viewed in a direction perpendicular to the second administration surface.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 16, 2021
    Assignee: TOPPAN PRINTING CO., LTD.
    Inventors: Hiroyuki Kato, Ichiro Takase
  • Patent number: 10920288
    Abstract: The present invention relates to methods and kits for detecting in a sample the presence of a virus particle or a virus-like particle that has reverse transcriptase activity and methods for preparing a retroviral contaminant-free substance. An aspect of the present invention is a method for detecting the presence of a virus particle in a sample of a Virus-like Particle (VLP) drug substance comprising a step of performing PCR-based reverse transcriptase (PBRT) on a sample of the VLP drug substance that has been treated with a protease.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: February 16, 2021
    Assignee: Takeda Vaccines, Inc.
    Inventors: Joel R. Haynes, Evelyn Benson
  • Patent number: 10912825
    Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: February 9, 2021
    Assignee: KJ Biosciences LLC
    Inventors: Yawei Ni, Jianhua Guo
  • Patent number: 10865389
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: December 15, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10858626
    Abstract: The present invention provides methods for producing and/or expanding tumor-infiltrating lymphocytes (TILs) that can be used in adoptive immunotherapy in cancer treatment.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: December 8, 2020
    Assignee: UNIVERSITÉ DE LAUSANNE
    Inventors: Marie-Agnes Doucey, Nicolas Guex, Isaac Crespo, Ioannis Xenarios
  • Patent number: 10858634
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 8, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10858633
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 8, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10821101
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating AIDS, comprising a rhodanine derivative and a nucleoside reverse transcriptase inhibitor. A complex composition of the present invention exhibits a synergistic effect in terms of anti-HIV activity as compared with a case where each of the compounds is used as a single drug. Thus, the composition provides sufficient anti-HIV activity and exhibits an excellent effect of decreasing side effects such as toxicity even in a case where each compound is administered in a small amount. Accordingly, the present invention is expected to greatly contribute to treatment of AIDS patients.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: November 3, 2020
    Assignee: AVIXGEN INC.
    Inventors: Min Jung Kim, Jun Sub Choi, Hye Cheong Koo, Yi Yong Baek
  • Patent number: 10821173
    Abstract: The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizing antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins. Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: November 3, 2020
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: James J. Mond, Clifford M. Snapper, Xinle Cui
  • Patent number: 10792354
    Abstract: An oral vaccine composition for fish, and related oral vaccine delivery system and methods for making and using such oral vaccine composition and delivery system are described. The oral vaccine composition includes virus-like particles effective to mediate an immunoprotective response in a target fish species, wherein the virus-like particles are contained in biomass of an organism or cell culture in which the virus-like particles have been expressed, optionally further including (i) adjuvant effective to enhance the immunoprotective response of the virus-like particles in the target fish species; (ii) encapsulant protectively associated with the virus-like particles for selective locus bioavailability in the target fish species; and/or (iii) binding agent aggregating the ingredients of the composition with one another.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: October 6, 2020
    Assignees: UNIVERSITY OF MARYLAND BALTIMORE COUNTY, ALLOTROPIC TECH, LLC
    Inventors: Vikram N. Vakharia, Robert Balcerzak
  • Patent number: 10772947
    Abstract: The invention provides human papillomavirus (HPV) antigen formulations which show increased antigen stability. More specifically, the invention provides stable HPV formulations comprising HPV virus-like particles (VLPs) bound to an aluminum salt adjuvant and further comprise a combination of sucrose and mannitol. The vaccine formulations of the invention are stable following freeze-thaw and freeze-drying. Also provided are lyophilized and frozen HPV vaccine formulations comprising HPV VLPs of at least one HPV type adsorbed onto an aluminum salt adjuvant, sucrose, and mannitol. Methods of making the stable vaccine formulations of the invention are also provided.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: September 15, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ramesh V. Chintala, Akhilesh Bhambhani
  • Patent number: 10738088
    Abstract: A non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) is provided herein, and methods of making and using the non-naturally occurring PRRSV also are provided.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: August 11, 2020
    Assignees: NUtech Ventures, The Board of Trustees of the University of Illinois
    Inventors: Hiep Lai Xuan Vu, Fernando Osorio, William W. Laegreid, Asit K. Pattnaik, Fangrui Ma
  • Patent number: 10731116
    Abstract: The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. The compositions of the invention are expected to ameliorate some of the negative side effects associated with the consumption of alcohol, such as hangover and facial flushing.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: August 4, 2020
    Assignee: Deuteria Beverages, LLC
    Inventors: Anthony W. Czarnik, Jeffrey A. McKinney
  • Patent number: 10702603
    Abstract: Aspects of the invention provide therapeutic recombinant protein preparations and methods of preparing therapeutic recombinant protein, which methods include contacting recombinant protein preparations with zwitterionic detergent at or above critical micelle concentration of the detergent.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 7, 2020
    Assignee: Biogen MA Inc.
    Inventors: Lynn Edward Conley, Yinying Tao
  • Patent number: 10668059
    Abstract: Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: June 2, 2020
    Assignee: Duke University
    Inventors: Soman N. Abraham, Ashley L. St. John
  • Patent number: 10668279
    Abstract: The disclosure is directed to a device for electroporating and delivering one or more antigens and a method of electroporating and delivering one or more antigens to cells of epidermal tissues using the device. The device comprises a housing, a plurality of electrode arrays projecting from the housing, each electrode array including at least one electrode, a pulse generator electrically coupled to the electrodes, a programmable microcontroller electrically coupled to the pulse generator, and an electrical power source coupled to the pulse generator and the microcontroller. The electrode arrays define spatially separate sites.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: June 2, 2020
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Kate Broderick, Jay McCoy, Stephen V. Kemmerrer
  • Patent number: 10660952
    Abstract: The present invention relates to a porcine parvovirus and porcine reproductive and respiratory syndrome virus vaccine for protecting a subject, preferably swine, against diseases associated with porcine parvovirus and porcine reproductive and respiratory syndrome virus. The present invention further relates to methods of producing immunogenic compositions as well as such immunogenic compositions exhibiting reduced virucidal activity.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 26, 2020
    Inventors: Troy James Kaiser, Jeremy Kroll, Eric Martin Vaughn
  • Patent number: 10654899
    Abstract: The present invention relates to a protein comprising a truncated version of the HSV-2 protein mg G-2, said protein comprising: (i) an extracellular region of mg G-2 (EX-mg G-2), or a truncated version thereof, of at least 285 amino acids; said extracellular region or truncated version thereof having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3; (ii) a truncated transmembrane region of mg G-2 (t-TMR-mg G-2) of 2 to 15 amino acids; said truncated transmembrane region having at least 90% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 6; and (iii) an intracellular region of mg G-2 (IC-mg G-2), or a truncated version thereof, of at least 18 amino acids; said intracellular region or truncated version thereof having at least 90% or 95% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: May 19, 2020
    Assignee: SIMPLEXIA AB
    Inventor: Jan-Åke Liljeqvist
  • Patent number: 10620204
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing ebolavirus and methods for use thereof. The present disclosure is directed to a method of detecting an ebolavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Table 2, or an antibody fragment thereof; and (b) detecting ebolavirus glycoprotein in said sample by binding of said antibody or antibody fragment to antigen in said sample. In still further embodiments, the present disclosure concerns immunodetection kits for use with the immunodetection methods described above.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 14, 2020
    Assignees: VANDERBILT UNIVERSITY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James E. Crowe, Jr., Andrew I. Flyak, Alexander Bukreyev, Philipp Ilinykh
  • Patent number: 10583189
    Abstract: The present invention relates to a therapy for treating or preventing several diseases in animals, based on the administration of a highly concentrated avian derived immunoglobulins formulation, obtained from the egg yolk from hens previously hiper-immunized with a vaccine formulation comprising infectious agents or toxins antigens, a light mineral oil and a particulate adjuvant.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: March 10, 2020
    Assignee: Investigacion Aplicada, S.A. DE C.V.
    Inventors: Eduardo Lucio Decanini, José Andrés Morales Garzon
  • Patent number: 10576142
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: March 3, 2020
    Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 10568955
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: February 25, 2020
    Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 10548915
    Abstract: The present invention is related to a combination for treating an EV71 infection, which comprises two or more compounds at each's non-effective level and provides an unexpected synergistic activity against EV71 replication, wherein the compound is selected from the group consisting of auranofin, ouabain, emetine, niclosamide, and S-(+)-fluoxetine.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: February 4, 2020
    Assignee: SUN JET BIOTECHNOLOGY INC.
    Inventors: Yeou Guang Tsay, Szu-Hao Kung
  • Patent number: 10526376
    Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: January 7, 2020
    Assignee: University of Copenhagen
    Inventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
  • Patent number: 10500268
    Abstract: Disclosed are compositions and methods for related to mutant influenza viruses with increased fidelity.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: December 10, 2019
    Assignee: University of Rochester
    Inventors: Andrew Cox, Stephen Dewhurst
  • Patent number: 10472647
    Abstract: Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: November 12, 2019
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Suzanne L. Tomchuck, Elizabeth B. Norton, Robert F. Garry, Bruce Bunnell, John D. Clements
  • Patent number: 10443040
    Abstract: Disclosed in the present application are: a method for preparing in vitro/ex vivo antigen-specific cytotoxic T-cells by using B cells treated with biological response modifier; and a use thereof. The cytotoxic T-cells prepared by the method of the present application can be used advantageously for treating infectious disease and cancer and the like.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 15, 2019
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Hyoung Jin Kang, Sun Ok Yun, Chang-Yuil Kang